Meeting
2018 ASCO Annual Meeting
Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL).
Authors
Chadi Nabhan
Cardinal Health Specialty Solutions, Dublin, OH
Chadi Nabhan , Andrew Klink , Choo Hyung Lee , Jalyna R. Laney , Yin Yang , Anna G. Purdum
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7545)
DOI
10.1200/JCO.2018.36.15_suppl.7545
Abstract #
7545
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.
First Author: He Huang
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.
First Author: Vivian Nguyen
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho